Date: 2015-08-20
Type of information: Collaboration agreement
Compound: monoclonal antibodies against Cellectis’ targets
Company: Cellectis (France) ModiQuest Research (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration development
Action mechanism: monoclonal antibody
Disease:
Details: * On March 6, 2015, ModiQuest Research BV, the Dutch antibody services company, announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s). During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™.
Financial terms: Financial details of the collaboration were not disclosed.
Latest news:
